Peptide Catalog

A small-molecule NNMT inhibitor (technically not a peptide) grouped with peptides in fat-loss contexts, investigated in preclinical obesity and muscle-aging models.

An experimental chimeric peptide that targets prohibitin on adipose vasculature, inducing apoptosis of blood vessels feeding white fat tissue. Studied in obese primates with dramatic fat reduction but no human trials to date.

A small-molecule anti-inflammatory agent repurposed for metabolic research, studied as an IKKε/TBK1 inhibitor that may reverse obesity-associated insulin resistance.

A counter-regulatory heptapeptide of the renin-angiotensin system that opposes the vasoconstrictive and pro-inflammatory effects of angiotensin II through the Mas receptor, with cardioprotective, anti-fibrotic, and anti-inflammatory properties.

A 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176–191), marketed for fat-loss lipolytic activity but weak in controlled human trials.

A topical hexapeptide marketed as a 'topical Botox' — mimics a SNAP-25 fragment to dampen neurotransmitter release at the dermal-epidermal junction.

A 15-amino-acid peptide fragment derived from gastric juice protein BPC, studied extensively in animal models for tissue healing and gut integrity.

An FDA-approved melanocortin-4 receptor agonist (Vyleesi®) for hypoactive sexual desire disorder in premenopausal women — the first centrally-acting peptide approved for female sexual dysfunction.

A long-acting amylin analog in development by Novo Nordisk, studied in combination with semaglutide (CagriSema) for obesity — achieving up to 24% weight loss in trials.

A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids, approved in over 40 countries for stroke recovery and traumatic brain injury.

The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.

A modified GHRH (1-29) analog without the Drug Affinity Complex — produces discrete, pulsatile GH release with a ~30-minute half-life, closely mimicking endogenous GH secretion patterns.

Enzymatically hydrolyzed collagen broken into short peptides that survive digestion — marketed for skin, joint, and connective-tissue support.

A copper-binding tripeptide (Ala-His-Lys-Cu) studied for hair follicle stimulation, dermal papilla cell proliferation, and VEGF upregulation in hair growth applications.

A hexapeptide analog of angiotensin IV that crosses the blood-brain barrier and promotes synaptogenesis via hepatocyte growth factor (HGF) signaling — studied for cognitive enhancement and neurodegenerative disease.

A 9-amino-acid neuropeptide isolated from the rabbit brain, investigated for delta-wave sleep promotion and stress-axis modulation.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on pineal extract Epithalamin — studied by Russian researchers for telomerase, circadian, and longevity endpoints.

Alternate naming and formulation of the tetrapeptide Ala-Glu-Asp-Gly (AEDG), sometimes sold distinctly from Epitalon — same active sequence targeting telomerase activation.

A 344-amino-acid glycoprotein that antagonizes myostatin and activin A — the primary endogenous brake on skeletal muscle growth — studied for muscle wasting and gene therapy applications.

A D-retro-inverso peptide that disrupts FOXO4-p53 interactions in senescent cells, triggering selective apoptosis. The first peptide-based senolytic — published in Cell (2017) with striking mouse healthspan data.

A naturally occurring copper-binding tripeptide (Gly-His-Lys) with decades of cosmetic dermatology research in wound healing and skin remodeling.

The base copper-binding tripeptide (Gly-His-Lys) found in human plasma and tissues — a precursor to GHK-Cu with intrinsic bioactivity in wound healing, gene modulation, and anti-inflammatory signaling.

An early-generation growth-hormone-releasing peptide with potent GHSR agonism but notable prolactin elevation compared to the later selective agent Ipamorelin.

The first-generation growth-hormone-releasing peptide, notable for inducing strong hunger through ghrelin-receptor activation alongside GH release.

A naturally occurring tripeptide cleaved from the N-terminus of IGF-1 in the brain, studied as a neuroprotective agent in stroke and neurodegeneration models.

A potent GHRP with documented cardioprotective effects in ischemic animal models, distinct from other GHRPs in its non-GH receptor activity.

A modified fragment of human growth hormone (amino acids 176-191) that retains GH's lipolytic activity without its growth-promoting or diabetogenic effects. The most targeted fat-loss peptide in research use.

A 24-amino-acid mitochondrial-derived peptide (MDP) with cytoprotective, anti-apoptotic, and neuroprotective activity. Encoded within the mitochondrial genome, humanin represents a new class of retrograde signaling molecules.

An oral, non-peptide growth hormone secretagogue that mimics ghrelin at the GHSR-1a receptor — produces sustained GH and IGF-1 elevation without injections. Extensively studied in human trials.

A long-acting analog of insulin-like growth factor 1 with substitutions that reduce IGF-binding-protein affinity, extending half-life and increasing free IGF-1 activity.

The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.

A 10-amino-acid fragment of the endogenous kisspeptin neuropeptide that activates GnRH neurons — the master switch of the reproductive hormone axis — studied for infertility, metabolic health, and diagnostic endocrinology.

A C-terminal tripeptide fragment of alpha-MSH with potent anti-inflammatory activity, studied for its role in modulating NF-κB signaling without melanogenic effects.

A synthetic octapeptide tight junction regulator studied in Phase III clinical trials for celiac disease — acts locally in the gut to prevent paracellular permeability increase (leaky gut).

The first GLP-1 receptor agonist approved for chronic weight management (Saxenda, 2014) — an acylated human GLP-1 analog with ~13-hour half-life dosed once daily.

A 37-amino-acid human cathelicidin antimicrobial peptide with broad-spectrum activity against bacteria, fungi, and biofilms, plus immunomodulatory and wound-healing properties.

Fish-derived hydrolyzed collagen — smaller molecular weight than bovine, often claimed to have superior bioavailability though head-to-head evidence is limited.

A well-studied topical peptide combination marketed for wrinkle reduction — the palmitoyl lipid tail enables penetration past the stratum corneum.

A synthetic analog of α-MSH that binds melanocortin receptors, inducing melanogenesis (tanning) along with libido and appetite-suppression effects. Pre-PT-141 ancestor molecule.

A splice variant of IGF-1 produced locally in damaged muscle tissue, studied for its role in satellite cell activation and skeletal muscle repair.

A 16-amino-acid peptide encoded in the mitochondrial 12S rRNA — investigated as a metabolic regulator of AMPK signaling and insulin sensitivity.

An N-acetylated, amidated analog of Selank with improved metabolic stability and enhanced CNS bioavailability — studied for anxiolytic and nootropic effects.

An off-label, ultra-low-dose application of the opioid antagonist naltrexone that paradoxically upregulates endogenous endorphin and enkephalin production, widely explored for autoimmune modulation and chronic inflammation.

A nine-amino-acid neuropeptide produced in the hypothalamus. The 'bonding hormone' has well-established roles in labor, lactation, and social cognition, with emerging research in autism, PTSD, and metabolic regulation.

A lipidated derivative of the copper-binding tripeptide GHK, designed for enhanced skin penetration in topical anti-aging formulations.

A lipopeptide signal peptide (INCI: Palmitoyl Tripeptide-1) used in Matrixyl and advanced skincare formulations to stimulate collagen I, III, and fibronectin synthesis via TGF-β activation.

PEGylated Mechano Growth Factor — a splice variant of IGF-1 modified with polyethylene glycol for extended half-life. Studied for its role in muscle satellite cell activation and tissue repair.

A polyethylene glycol-conjugated variant of BPC-157 engineered for extended half-life and reduced injection frequency while retaining the parent peptide's tissue-healing properties.

A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women, acting on central nervous-system pathways rather than vascular ones.

An investigational triple GIP / GLP-1 / glucagon receptor agonist from Eli Lilly, showing the largest weight-loss effect sizes yet reported in obesity trials (up to ~24% at 48 weeks in phase-2).

A synthetic heptapeptide analog of tuftsin, developed at the Russian Institute of Molecular Genetics as an anxiolytic nootropic administered intranasally.

Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.

A synthetic heptapeptide fragment of ACTH (4-10) developed in Russia as a cognitive enhancer, used clinically there for stroke recovery and anxiety.

The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.

An MC4R-selective melanocortin agonist FDA-approved for rare genetic obesity syndromes (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome).

A cell-permeable tetrapeptide that targets the inner mitochondrial membrane, stabilizing cardiolipin and improving electron transport chain efficiency — in late-stage clinical trials for mitochondrial and cardiac diseases.

A cell-permeable autophagy-inducing peptide derived from a key region of the Beclin 1 protein fused to the HIV-1 Tat transduction domain, engineered to potently activate cellular self-cleaning pathways.

Synthetic fragment of Thymosin β4 investigated for actin-binding, cell migration, and tissue repair across muscle, cornea, and cardiac models.

FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.

A thymic peptide bioregulator developed by the St. Petersburg Institute of Bioregulation and Gerontology, studied in Russian clinical cohorts for immune reconstitution and longevity.

A 28-amino-acid thymic peptide approved in 30+ countries (not US) for hepatitis B/C and as an immune adjunct in oncology and infectious disease.

A lesser-studied member of the beta-thymosin family with documented angiogenic and tumor-associated properties, investigated as both a cancer biomarker and a potential modulator of vascular growth.

A 43-amino acid peptide and the primary intracellular G-actin sequestering protein. TB-500 is a synthetic fragment of Thymosin Beta-4's active site — this is the full-length parent molecule with broader tissue repair and anti-inflammatory evidence.

A zinc-dependent nonapeptide hormone naturally secreted by thymic epithelial cells, studied for its role in T-cell maturation and immune system regulation.

First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.

A 28-amino-acid neuropeptide with broad immunomodulatory, vasodilatory, and neuroprotective activity. Studied in CIRS (chronic inflammatory response syndrome), pulmonary hypertension, and gut motility disorders.